Chronic haloperidol-induced alterations in pallidal GABA and striatal D1-mediated dopamine turnover as measured by dual probe microdialysis in rats

Neuroscience

Volumn 100, Issue 3, 2000, Pages 507-514

  Grimm, J W ^a   See, R E ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antipsychotic; Basal ganglia; Dihydrexidine; Female; GABA; Tardive dyskinesia

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; DIHYDREXIDINE; HALOPERIDOL; HOMOVANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG INDUCED DISEASE; FEMALE; GLOBUS PALLIDUS; MASTICATION; MICRODIALYSIS; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMAL; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; HALOPERIDOL; MASTICATION; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS;

EID: 0034721573     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00310-9     Document Type: Article

References (51)

1. Aravagiri M., Marder S.R., Van Putten T., Marshall B.D. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. J. Chromatogr. B Biomed. Appl. 656:1994;373-381.
2. Bourdelais A., Kalivas P.W. High sensitivity HPLC assay for GABA in brain dialysis studies. J. Neurosci. Meth. 39:1991;115-121.
3. Calabresi P., Centonze D., Gubellini P., Marfia G.A., Pisani A., Sancesario G., Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 61:2000;231-265.
4. Chapman M.A., See R.E. Differential effects of unique profile antipsychotic drugs on extracellular amino acids in the ventral pallidum and globus pallidus of rats. J. Pharmac. exp. Ther. 277:1996;1586-1594.
5. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 19:1996;417-422.
6. Darney K.J. Jr., Lewis M.H., Brewster W.K., Nichols D.E., Mailman R.B. Behavioral effects in the rat of dihydrexidine, a high-potency, full- efficacy D1 dopamine receptor agonist. Neuropsychopharmacology. 5:1991;187-195.
7. Delfs J.M., Ellison G.D., Mercugliano M., Chesselet M.F. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Expl Neurol. 133:1995;175-188.
8. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev. Neurosci. 5:1994;27-41.
9. Drew K.L., O'Connor W.T., Kehr J., Ungerstedt U. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur. J. Pharmac. 187:1990;385-397.
10. Ellison G., Johansson P., Levin E., See R., Gunne L. Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats. Psychopharmacology. 96:1988;253-257.
11. Ferre S., Cortes R., Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J. Neurosci. 14:1994;4839-4846.
12. Fields J.Z., Gordon J.H. Permanent haloperidol-induced dopamine receptor up-regulation in the ovariectomized rat. Brain Res. Bull. 26:1991;549-552.
13. Gale K. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature. 283:1980;569-570.
14. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. Jr, Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
15. Glazer W.M., Moore D.C., Bowers M.D. Jr., Brown W.A. Serum prolactin and tardive dyskinesia. Am. J. Psychiat. 138:1981;1493-1496.
16. Grimm J.W., Aravagiri M., See R.E. Ovariectomy results in lower plasma haloperidol levels in rats following chronic administration. Pharmac. Res. 15:1998;1640-1642.
17. Gunne L.M., Andren P.E. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin. Neuropharmac. 16:1993;90-95.
18. Gunne L.M., Haggstrom J.E. Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology. 81:1983;191-194.
19. Hatta Y., Hatta S., Saito T. Effects of ceruletide on the dopamine receptor-adenylate cyclase system in striatum and frontal cortex of rats chronically treated with haloperidol. Psychopharmacology. 110:1993;383-389.
20. Ichikawa J., Meltzer H.Y. Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J. Pharmac. exp. Ther. 256:1991;348-357.
21. Imperato A., Tanda G., Frau R., Di Chiara G. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J. Pharmac. exp. Ther. 245:1988;257-264.
22. Jeste D.V., Lohr J.B., Manley M. Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology. 106:1992;154-160.
23. Kurata K., Shibata R. Biphasic effect of locally applied apomorphine and 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine on the release of striatal dopamine investigated by means of brain dialysis. Neurosci. Lett. 117:1990;264-268.
24. Laruelle M., Jaskiw G.E., Lipska B.K., Kolachana B., Casanova M.F., Kleinman J.E., Weinberger D.R. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res. 575:1992;47-56.
25. Mottola D.M., Brewster W.K., Cook L.L., Nichols D.E., Mailman R.B. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J. Pharmac. exp. Ther. 262:1992;383-393.
26. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia- thalamo-cortical loop. Brain Res. Brain Res. Rev. 20:1995;91-127.
27. Paxinos G., Watson D. The Rat Brain in Stereotaxic Coordinates. 1986;Academic, New York.
28. Robertson G.S., Vincent S.R., Fibiger H.C. D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience. 49:1992;285-296.
29. Robinson T.E., Whishaw I.Q. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res. 450:1988;209-224.
30. Rosengarten H., Schweitzer J.W., Friedhoff A.J. Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci. 33:1983;2479-2482.
31. Rupniak N.M., Hall M.D., Mann S., Fleminger S., Kilpatrick G., Jenner P., Marsden C.D. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem. Pharmac. 34:1985;2755-2763.
32. Ruskin D.N., Rawji S.S., Walters J.R. Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393. J. Pharmac. exp. Ther. 286:1998;272-281.
33. Sasaki T., Kennedy J.L., Nobrega J.N. Localized changes in GABA receptor-gated chloride channel in rat brain after long-term haloperidol: relation to vacuous chewing movements. Synapse. 25:1997;73-79.
34. Scheel-Kruger J. Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta neurol. scand. Suppl. 107:1986;1-54.
35. See R.E. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci. Lett. 129:1991;265-268.
36. See R.E. Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia. Neuropsychopharmacology. 9:1993;101-109.
37. See R.E., Aravagiri M., Ellison G.D. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors. Life Sci. 44:1989;229-236.
38. See R.E., Chapman M.A. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmac. 263:1994;269-276.
39. See R.E., Chapman M.A. The consequences of long-term antipsychotic drug administration on basal ganglia neuronal function in laboratory animals. Crit. Rev. Neurobiol. 8:1994;85-124.
40. See R.E., Chapman M.A., Meshul C.K. Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. Synapse. 12:1992;147-154.
41. See R.E., Lynch A.M. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. NeuroReport. 6:1995;1795-1798.
42. See R.E., Lynch A.M., Aravagiri M., Nemeroff C.B., Owens M.J. Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats. Brain Res. 704:1995;202-209.
43. See R.E., Murray C.E. Changes in striatal dopamine release and metabolism during and after subchronic haloperidol administration in rats. Neurosci. Lett. 142:1992;100-104.
44. See R.E., Sorg B.A., Chapman M.A., Kalivas P.W. In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists. Neuropharmacology. 30:1991;1269-1274.
45. Shirakawa O., Tamminga C.A. Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Expl Neurol. 127:1994;62-69.
46. Soares K.V.S., McGrath J.J. The treatment of tardive dyskinesia - a systematic review and meta-analysis. Schizophr. Res. 39:1999;1-16.
47. Steele T.D., Hodges D.B. Jr., Levesque T.R., Locke K.W. D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats. Pharmac. Biochem. Behav. 58:1997;477-483.
48. Steele T.D., Hodges D.B. Jr., Levesque T.R., Locke K.W., Sandage B.W. Jr. The D1 agonist dihydrexidine releases acetylcholine and improves cognition in rats. Ann. N.Y. Acad. Sci. 777:1996;427-430.
49. Volonte M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190.
50. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology. 101:1990;431-447.
51. Yassa R., Jeste D.V. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull. 18:1992;701-715.